PPMX T003
Alternative Names: PPMX-T003Latest Information Update: 19 Jul 2023
At a glance
- Originator Perseus Proteomics
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Transferrin receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Large granular lymphocytic leukaemia
- Phase I Polycythaemia vera
- No development reported Haematological malignancies
Most Recent Events
- 19 Jul 2023 PPMX T003 is still in trials for Polycythaemia-vera in Japan (NCT05863234)
- 28 Jun 2023 No recent reports of development identified for phase-I development in Polycythaemia-vera in Japan (IV)
- 28 Jun 2023 No recent reports of development identified for preclinical development in Haematological-malignancies in Japan (IV)